Oral 10:RI Therapy・PRRT3

[1-MO10-2] Factors affecting the external dose rate on the day after Lu-177 DOTATATE therapy

Naoto Wakabayashi^1,3、Shiro Watanabe^2,3、Satoshi Takeuchi^4,5、Takahiro Tsuchikawa^4,6、Kenji Hirata^2,3,4、Rina Kimura³、Junki Takenaka^2,3、Hiroshi Ishii^2,3、Toshikazu Nambu¹、Kohsuke Kudo³ (1.Hokkaido cancer center, Sapporo, Japan、2.Department of Nuclear Medicine, Hokkaido University hospital, Sapporo, Japan、3.Department of Diagnostic and Interventional Radiology, Faculty of Medicine, Hokkaido University, Sapporo, Japan、4.Neuroendocrine neoplasm center, Hokkaido University hospital, Sapporo, Japan、5.Department of Medical Oncology Hokkaido University Graduate School of Medicine、6.Department of Gastroenterological Surgery II, Hokkaido University hospital, Sapporo, Japan)